Immunotherapy in prostate cancer: current state and future perspectives
暂无分享,去创建一个
[1] A. Jemal,et al. Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.
[2] W. V. van Weerden,et al. Construction of a chimeric antigen receptor bearing a nanobody against prostate a specific membrane antigen in prostate cancer , 2019, Journal of cellular biochemistry.
[3] P. Kantoff,et al. Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade , 2019, JAMA oncology.
[4] D. Siemens,et al. The Tumor Immune Contexture of Prostate Cancer , 2019, Front. Immunol..
[5] PSCA-CAR T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer , 2019, Case Medical Research.
[6] P. Kantoff,et al. Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] M. Galsky,et al. Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650). , 2019, Journal of Clinical Oncology.
[8] R. Jeraj,et al. FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab , 2019, Journal of Immunotherapy for Cancer.
[9] Haiyuan Yu,et al. CART cell therapy for prostate cancer: status and promise , 2019, OncoTargets and therapy.
[10] E. Purdy. American Association for Cancer Research (AACR) , 2018, The Grants Register 2022.
[11] N. Rezaei,et al. Passive-specific immunotherapy with monoclonal antibodies for prostate cancer: A systematic review , 2018, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[12] M. Cooperberg,et al. The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target , 2018, Journal of the National Cancer Institute.
[13] K. Ullah,et al. The application of prostate specific membrane antigen in CART‑cell therapy for treatment of prostate carcinoma (Review). , 2018, Oncology reports.
[14] J. Gulley,et al. Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy , 2018, Expert review of vaccines.
[15] P. Ott,et al. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] Hans Anton Schlößer,et al. Cytokine release syndrome , 2018, Journal of Immunotherapy for Cancer.
[17] D. McNeel,et al. Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine , 2018, Journal of Immunotherapy for Cancer.
[18] J. Schlom,et al. Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors , 2018, Clinical Cancer Research.
[19] Ximing J. Yang,et al. Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8+ T-cells Derived from Patients with Metastatic Castrate-resistant Disease. , 2017, European urology.
[20] Maryam Yousefi,et al. Placenta-specific1 (PLAC1) is a potential target for antibody-drug conjugate-based prostate cancer immunotherapy , 2017, Scientific Reports.
[21] P. Keegan,et al. First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication. , 2017, The New England journal of medicine.
[22] Anping Li,et al. Recent advances of bispecific antibodies in solid tumors , 2017, Journal of Hematology & Oncology.
[23] R. de Wit,et al. Systematic Review of Immune Checkpoint Inhibition in Urological Cancers. , 2017, European urology.
[24] S. Koch,et al. 1149PResults of the randomized, placebo-controlled phase I/IIB trial of CV9104, an mRNA based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC) , 2017 .
[25] N. Sardesai,et al. Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody , 2017, Cancer Immunology, Immunotherapy.
[26] D. McNeel,et al. Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination , 2017, Journal for immunotherapy of cancer.
[27] F. Montorsi,et al. PD-L1 Expression and CD8+ T-cell Infiltrate are Associated with Clinical Progression in Patients with Node-positive Prostate Cancer. , 2017, European urology focus.
[28] I. Svane,et al. Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study. , 2017, Cytotherapy.
[29] R. Loberg,et al. Clinical Pharmacology and Translational Aspects of Bispecific Antibodies , 2017, Clinical and translational science.
[30] Y. Nordby,et al. The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort , 2017, Oncotarget.
[31] I. Mellman,et al. Elements of cancer immunity and the cancer–immune set point , 2017, Nature.
[32] N. Bander,et al. Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer. , 2016, Urologic oncology.
[33] D. McNeel,et al. Immunotherapy for prostate cancer: False promises or true hope? , 2016, Cancer.
[34] A. Kibel,et al. Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial , 2016, Clinical Cancer Research.
[35] W. Zimmer,et al. Synergistic immunologic targets for the treatment of prostate cancer , 2016, Experimental biology and medicine.
[36] Charles G. Drake,et al. Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer , 2016, Oncotarget.
[37] H. Samaratunga,et al. Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis , 2016, Targeted Oncology.
[38] A. Makrigiannis,et al. Licensed and Unlicensed NK Cells: Differential Roles in Cancer and Viral Control , 2016, Front. Immunol..
[39] R. Montironi,et al. Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier? , 2016, Oncology reviews.
[40] Y. Shentu,et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.
[41] J. McQuade,et al. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. , 2016, Cancer discovery.
[42] G. Kristiansen,et al. The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer , 2015, Clinical Cancer Research.
[43] Wei Yuan,et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. , 2015, The New England journal of medicine.
[44] C. Rudin,et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[45] M. Scott Lucia,et al. Paucity of PD-L1 Expression in Prostate Cancer: Innate and Adaptive Immune Resistance , 2015, Prostate Cancer and Prostatic Disease.
[46] M. Karin,et al. Immune Infiltration and Prostate Cancer , 2015, Front. Oncol..
[47] K. Miller,et al. Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study , 2015, Journal of Immunotherapy for Cancer.
[48] M. Babjuk,et al. Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer , 2015, Oncotarget.
[49] W. Oh,et al. Autologous dendritic cell vaccination (DCVAC/PCa) added to docetaxel chemotherapy in a double-blind, randomized phase III trial (VIABLE) in men with advanced (mCRPC) prostate cancer. , 2015 .
[50] C. Redfern,et al. A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer , 2015, Clinical Cancer Research.
[51] Martin L. Miller,et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.
[52] A. Thakur,et al. Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients , 2015, Prostate cancer.
[53] T. Devries,et al. Combining immunotherapy and radiation for prostate cancer. , 2015, Clinical genitourinary cancer.
[54] M. Millenson,et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.
[55] C. June,et al. Going viral: chimeric antigen receptor T‐cell therapy for hematological malignancies , 2015, Immunological reviews.
[56] A. Stenzl,et al. mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer , 2014, Human vaccines & immunotherapeutics.
[57] S. Mandl,et al. Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy , 2014, Journal of Immunotherapy for Cancer.
[58] P. Carroll,et al. Activated Lymphocyte Recruitment Into the Tumor Microenvironment Following Preoperative Sipuleucel-T for Localized Prostate Cancer , 2014, Journal of the National Cancer Institute.
[59] N. Agarwal,et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. , 2014, The Lancet. Oncology.
[60] R. Madan,et al. Poxviral-based vaccine elicits immunologic responses in prostate cancer patients , 2014, Oncoimmunology.
[61] E. Giannoni,et al. The Role of M1 and M2 Macrophages in Prostate Cancer in relation to Extracapsular Tumor Extension and Biochemical Recurrence after Radical Prostatectomy , 2014, BioMed research international.
[62] R. Junghans,et al. Advanced generation anti‐prostate specific membrane antigen designer T Cells for prostate cancer immunotherapy , 2014, The Prostate.
[63] M. Stratton,et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[64] S. Steinberg,et al. Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer , 2013, Cancer Immunology Research.
[65] Andressa Ardiani,et al. Combination Therapy with a Second-Generation Androgen Receptor Antagonist and a Metastasis Vaccine Improves Survival in a Spontaneous Prostate Cancer Model , 2013, Clinical Cancer Research.
[66] I. Mellman,et al. Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.
[67] Stanley J. Goldsmith,et al. Phase II Study of Lutetium-177–Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer , 2013, Clinical Cancer Research.
[68] I. Lowy,et al. T cell profiling reveals high CD4+CTLA-4+ T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment , 2013, Cancer Immunology, Immunotherapy.
[69] Michel Sadelain,et al. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells , 2012, Nature Biotechnology.
[70] G. Sauter,et al. Intratumoral T but not B lymphocytes are related to clinical outcome in prostate cancer , 2012, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[71] M. Morris,et al. A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[72] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[73] I. Lowy,et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.
[74] S. Steinberg,et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.
[75] M. Morris,et al. Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial , 2012, Cancer Chemotherapy and Pharmacology.
[76] H. Scher,et al. Ipilimumab (IPI) in metastatic castrate-resistant prostate cancer (mCRPC): Results from an open-label, multicenter phase I/II study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[77] L. Aguilar,et al. Cytotoxic immunotherapy strategies for cancer: Mechanisms and clinical development , 2011, Journal of cellular biochemistry.
[78] Jenna M. Sullivan,et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity , 2011, The Journal of Experimental Medicine.
[79] P. Schellhammer,et al. Randomized Trial of Autologous Cellular Immunotherapy with Sipuleucel-T in Androgen-Dependent Prostate Cancer , 2011, Clinical Cancer Research.
[80] M. Kami,et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010 .
[81] Jenna M. Sullivan,et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity , 2010, The Journal of experimental medicine.
[82] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[83] C. Drake. Prostate cancer as a model for tumour immunotherapy , 2010, Nature Reviews Immunology.
[84] P. Kantoff,et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.
[85] D. McNeel,et al. DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) Elicits Long-term T-cell Responses in Patients With Recurrent Prostate Cancer , 2010, Journal of immunotherapy.
[86] Louis M. Weiner,et al. Monoclonal antibodies: versatile platforms for cancer immunotherapy , 2010, Nature Reviews Immunology.
[87] S. Cingarlini,et al. IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer. , 2010, Vaccine.
[88] P. Kantoff,et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[89] T. Ratliff,et al. Phase I Clinical Trial of an Adenovirus/Prostate-Specific Antigen Vaccine for Prostate Cancer: Safety and Immunologic Results , 2009, Clinical Cancer Research.
[90] D. McNeel,et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[91] A. Mes-Masson,et al. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. , 2009, Journal of immunological methods.
[92] P. Schellhammer,et al. Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer , 2009, Cancer.
[93] Kevin M. Prise,et al. Radiation-induced bystander signalling in cancer therapy , 2009, Nature Reviews Cancer.
[94] H. Schneider,et al. CD28 and CTLA‐4 coreceptor expression and signal transduction , 2009, Immunological reviews.
[95] M. Hussein,et al. Phenotypic characterization of the infiltrating immune cells in normal prostate, benign nodular prostatic hyperplasia and prostatic adenocarcinoma. , 2009, Experimental and molecular pathology.
[96] S. Steinberg,et al. Analysis of Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer Treated with Vaccine, Nilutamide, and Combination Therapy , 2008, Clinical Cancer Research.
[97] S. Steinberg,et al. Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma , 2008, Clinical Cancer Research.
[98] H. Scher,et al. Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. , 2008, Journal of Clinical Oncology.
[99] K. Wiesmüller,et al. Mimotope vaccines for cancer immunotherapy. , 2007, Vaccine.
[100] H. Naim,et al. Use of viral vectors for the development of vaccines , 2007, Expert review of vaccines.
[101] D. McNeel,et al. Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells , 2007, Cancer Immunology, Immunotherapy.
[102] E. Small,et al. A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer , 2007, Clinical Cancer Research.
[103] P. Schellhammer,et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[104] K. Camphausen,et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy , 2006, The Journal of experimental medicine.
[105] E. B. Butler,et al. Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[106] S. Steinberg,et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.
[107] S. Larson,et al. Pilot Trial of Unlabeled and Indium-111–Labeled Anti–Prostate-Specific Membrane Antigen Antibody J591 for Castrate Metastatic Prostate Cancer , 2005, Clinical Cancer Research.
[108] T. Heng,et al. Activation of Thymic Regeneration in Mice and Humans following Androgen Blockade , 2005, The Journal of Immunology.
[109] Shankar Vallabhajosula,et al. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[110] E. Small,et al. Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer. , 2005, Clinical prostate cancer.
[111] B. Wüthrich,et al. Direct intralymphatic injection of peptide vaccines enhances immunogenicity , 2005, European journal of immunology.
[112] S. Vallabhajosula,et al. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[113] J. Manola,et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[114] H. Kaufman,et al. Poxvirus vaccines for cancer and HIV therapy , 2004, Expert opinion on biological therapy.
[115] E. B. Butler,et al. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. , 2004, International journal of radiation oncology, biology, physics.
[116] R. Zinkernagel,et al. Intralymphatic immunization enhances DNA vaccination , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[117] D. Siemens,et al. Cutting Edge: Restoration of the Ability to Generate CTL in Mice Immune to Adenovirus by Delivery of Virus in a Collagen-Based Matrix , 2001, The Journal of Immunology.
[118] J. Schlom,et al. A triad of costimulatory molecules synergize to amplify T-cell activation. , 1999, Cancer research.
[119] José Luis de la Pompa,et al. Negative Regulation of PKB/Akt-Dependent Cell Survival by the Tumor Suppressor PTEN , 1998, Cell.
[120] N. Bander,et al. MHC class I and II expression in prostate carcinoma and modulation by interferon‐alpha and ‐gamma , 1997, The Prostate.
[121] M. Goris,et al. Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[122] J. Eastham,et al. Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. , 1996, Human gene therapy.
[123] M. Moser,et al. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo , 1994, European journal of immunology.
[124] S. Freeman,et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. , 1993, Cancer research.
[125] R. Miller,et al. Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine. , 1978, The Journal of biological chemistry.
[126] P. K. Strangway,et al. Erratum , 1970, American Political Science Review.
[127] P. Hwu,et al. Chimeric antigen receptor T-cell therapy — assessment and management of toxicities , 2018, Nature Reviews Clinical Oncology.
[128] G. Finocchiaro,et al. Immunotherapy with dendritic cells loaded with glioblastoma stem cells: from preclinical to clinical studies , 2015, Cancer Immunology, Immunotherapy.
[129] A. Abbas,et al. IMMUNITY TO TUMORS , 2010 .
[130] H. Scher,et al. Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC) DOD Grant Log# PC081632, PI: Slovin, SF , 2008 .
[131] M. Schmidt,et al. Androgens regulate the immune/inflammatory response and cell survival pathways in rat ventral prostate epithelial cells. , 2006, Endocrinology.